Sobrevida de los pacientes con carcinoma hepatocelular tratados con quimioembolización con microesferas cargadas: experiencia en un hospital de alta complejidad Thesis

short description

  • Postgraduate thesis

Thesis author

  • Lara Cárdenas, July Patricia

external tutor

  • Pérez Hidalgo, Juan Manuel


  • Hepatocellular carcinoma (HCC) is the second cause of death related to cancer worldwide, in Colombia an incidence of 2 cases per 100,000 habitants is estimated; worldwide hepatitis B and C viruses are the most important risk factors for the development of cirrhosis and HCC, however, alcohol is the leading cause in our country. Without treatment, patients with HCC have a survival of 1 to 10% at 5 years, but with prevention strategies, early diagnosis and proper treatment, the survival of these patients has improved to more than 50%, depending of Child-Pugh stage. Among the treatment options (surgery, locoregional treatment or systemic therapy), chemoembolization with microsphere has shown multiple benefits such as increased survival (near to 26 months), progression-free time (76% to 6 months), stable disease in 95% and decreased tumor volume, the latter evaluated in imaging studies and related to serum alpha-fetoprotein levels, however, it should be noted that this type of treatment is not innocuous and can lead to serious complications in a 4.5 to 12 %. Our objective is to estimate in a historical cohort the survival of patients with HCC treated with chemoembolization with microsphere in the Fundación Cardioinfantil from 2010 to 2018, analyzing different variables, to obtain results in accordance with the literature, evaluate our experience and contribute to the generation of own evidence, as a basis for future studies in this field.

publication date

  • August 9, 2021 1:46 PM


  • Analysis of the tumor response of Hepatocellular Carcinoma (HCC) to Chemoembolization
  • Evaluation of the survival rate to Hepatocarcinoma treated with Chemoembolization with Charged Microspheres
  • Experience in the treatment of HCC by Chemoembolization
  • Life time analysis of cirrhotic patients treated with DEB-TACE
  • Locoregional management with DEB-TACE of focal liver lesions
  • Transarterial Chemoembolization with Drug Releasing Beads (DEB-TACE)

Document Id

  • 9c01cb25-004c-428f-b3d6-3487a94a04e4